Even so, within the scope of overall patients with advanced NSCLC, treatment-related grade 3-4 toxic effects in PD-1/PD-L1 arm occurred less frequently than in chemotherapy arm in randomized trials (7%-26.6% vs 35%-55%) [24-27, 34, 35]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.